Upgrade to SI Premium - Free Trial

MBCOF (MBCOF)

0.07 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Latest Headlines

Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site October 19, 2026 6:45 AM - Globe NewsWire Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model October 8, 2026 6:45 AM - Globe NewsWire Marvel Biosciences signs letter of intent for Phase 1 trial of MB-204 October 6, 2026 6:45 AM - StreetInsider Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update October 6, 2026 6:45 AM - Globe NewsWire Marvel Biosciences closes private placement raising $1.6 million September 29, 2026 5:53 PM - StreetInsider Marvel Biosciences Announces Closing of Private Placement For Up To $3.0 Million September 29, 2026 5:53 PM - StreetInsider Marvel Biosciences updates non-brokered private placement of up to $3M September 17, 2026 5:06 PM - StreetInsider Marvel Biosciences Provides Update on Private Placement for up to $3.0 Million September 17, 2026 5:06 PM - StreetInsider Marvel Biosciences extends private placement deadline to Sept. 14 September 9, 2026 2:33 PM - StreetInsider Marvel Biosciences Announces Extension to Closing Date of Private Placement September 9, 2026 2:33 PM - StreetInsider Marvel Biosciences extends private placement to Quebec investors August 19, 2026 1:07 PM - StreetInsider Marvel Biosciences Expands Private Placement to Quebec August 19, 2026 1:07 PM - StreetInsider Marvel Biosciences reports MB-204 preclinical results in Fragile X model August 5, 2026 5:00 AM - StreetInsider Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X August 5, 2026 5:00 AM - Globe NewsWire Full Article List